Join Growin Stock Community!

邦睿生技6955.TW Overview

TW StockBiotech. & Medical
(No presentation for 6955)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

邦睿生技（6955）Overall Performance

邦睿生技（6955）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

邦睿生技（6955） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

邦睿生技（6955）Key Information

邦睿生技（6955）Profile

邦睿生技（6955）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.88
PE Ratio (TTM)
42.24
Forward PE
-
PS Ratio (TTM)
14.17
PB Ratio
6.65
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
78.12%
Net Margin
33.54%
Revenue Growth (YoY)
12.34%
Profit Growth (YoY)
14.06%
3-Year Revenue Growth
19.37%
3-Year Profit Growth
22.41%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
3.88
PE Ratio (TTM)
42.24
Forward PE
-
PS Ratio (TTM)
14.17
PB Ratio
6.65
Price-to-FCF
-
Gross Margin
78.12%
Net Margin
33.54%
Revenue Growth (YoY)
12.34%
Profit Growth (YoY)
14.06%
3-Year Revenue Growth
19.37%
3-Year Profit Growth
22.41%
default symbol

6955

邦睿生技

164.00D

-3.66%

(-0.04)

  • When is 6955's latest earnings report released?

    The most recent financial report for 邦睿生技 (6955) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6955's short-term business performance and financial health. For the latest updates on 6955's earnings releases, visit this page regularly.

  • What is the operating profit of 6955?

    According to the latest financial report, 邦睿生技 (6955) reported an Operating Profit of 22.93M with an Operating Margin of 31.31% this period, representing a growth of 58.71% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6955's revenue growth?

    In the latest financial report, 邦睿生技 (6955) announced revenue of 73.26M, with a Year-Over-Year growth rate of 28.41%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6955 have?

    At the end of the period, 邦睿生技 (6955) held Total Cash and Cash Equivalents of 154.69M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6955 go with three margins increasing?

    In the latest report, 邦睿生技 (6955) achieved the “three margins increasing” benchmark, with a gross margin of 77.6%%, operating margin of 31.31%%, and net margin of 35.25%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6955's profit trajectory and future growth potential.

  • Is 6955's EPS continuing to grow?

    According to the past four quarterly reports, 邦睿生技 (6955)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6955?

    邦睿生技 (6955)'s Free Cash Flow (FCF) for the period is 4.65M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 78.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.